RxDoctor Payments Data

Cary Finn, MD

Internal Medicine · Memphis, TNNPI 1033192992

Payments from drug & device makers

$15,617in general payments, 2019–2025

Across 950 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AbbVie$2K
  • AstraZeneca$2K
  • Pfizer$1K
  • Lilly USA, LLC$950
  • Takeda Pharmaceuticals U.S.A., Inc.$780
  • plus $7K from 52 others

What the payments were for

  • Food & beverage$15,35598%
  • Education$2622%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk149$2,681
AbbVie(2 entities)126$1,613
AstraZeneca85$1,586
Pfizer92$1,359
Lilly USA, LLC61$950
Takeda Pharmaceuticals U.S.A., Inc.55$780
Amgen34$644
Bayer28$590
Boehringer Ingelheim35$571
Astellas Pharma US Inc18$530
Amarin Pharma, Inc.26$389
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC23$359
Merck23$335
Sanofi-aventis U.S. LLC19$291
GSK20$276
Abbott10$226
Biohaven Pharmaceuticals, Inc.15$208
Supernus Pharmaceuticals, Inc.11$198
Biohaven Pharmaceutical Holding Company Ltd.11$183
Ironwood Pharmaceuticals, Inc10$180
Corcept Therapeutics8$152
Phathom Pharmaceuticals, Inc.10$140
Johnson & Johnson6$106
Dexcom, Inc.6$104
Bausch Health US, LLC6$95
Xeris Pharmaceuticals, Inc.4$77
Axsome Therapeutics, Inc.3$75
Novartis4$73
Upsher-smith Laboratories LLC5$65
Teva Pharmaceuticals USA, Inc.4$61
Philips North America LLC1$55
Antares Pharma, Inc.3$55
Mannkind Corporation3$43
Otsuka America Pharmaceutical, Inc.3$41
Lundbeck LLC2$36
Acadia Pharmaceuticals Inc2$35
Vyera Pharmaceuticals, LLC2$34
Idorsia Pharmaceuticals US Inc2$32
Kowa Pharmaceuticals America, Inc.2$31
Esperion Therapeutics, Inc.2$29
Exact Sciences2$28
Adlon Therapeutics L.p.2$27
E.r. Squibb & Sons, L.L.C.2$26
Boston Scientific1$22
Edwards Lifesciences1$21
Heartflow, Inc.1$20
Scilex Pharmaceuticals Inc.1$20
Nevro Corp.1$18
Genentech USA, Inc.1$17
Sunovion Pharmaceuticals Inc.1$16
Seqirus USA Inc1$16
Tris Pharma Inc1$15
Electromed, Inc.1$15
Shire North American Group Inc1$14
IBSA Pharma Inc.1$14
Assertio Therapeutics, Inc.1$13
MDD US Operations, LLC1$13
Arbor Pharmaceuticals, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,617 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$458,802
Medicare patients
1,181
Services billed
17,365

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban147$152,149
JardianceEmpagliflozin124$118,195
OzempicSemaglutide121$116,950
MounjaroTirzepatide73$72,648
XareltoRivaroxaban70$59,966
JanuviaSitagliptin Phosphate48$56,299
LinzessLinaclotide46$41,750
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog47$33,643
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$29,251
Tresiba Flextouch U-200Insulin Degludec32$28,271
FarxigaDapagliflozin Propanediol25$26,914
Breo ElliptaFluticasone/Vilanterol47$25,310
JanumetSitagliptin Phos/Metformin Hcl20$22,668
MyrbetriqMirabegron26$19,900
TradjentaLinagliptin30$17,656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Paxlovid$1,359$171,987241 claims
Boehringer IngelheimJardiance, Tradjenta$571$135,851154 claims
Novo NordiskOzempic$2,681$116,950121 claims
MerckJanuvia, Janumet, Lagevrio (Eua)$335$85,34489 claims
Lilly USA, LLCMounjaro$950$72,64873 claims
AbbVieLinzess, Restasis, Synthroid$1,613$67,159183 claims
Johnson & JohnsonXarelto$106$59,96670 claims
GSKTrelegy Ellipta, Breo Ellipta$276$54,56293 claims
AstraZenecaFarxiga, Brilinta, Symbicort$1,586$42,04660 claims
Astellas Pharma US IncMyrbetriq$530$19,90026 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$291$12,06114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →